CJC-1295 (no DAC) Peptide For Sale
Buy CJC-1295 (no DAC) peptide: 2mg, 5mg, 10mg or 20mg listed purchase quantities. Compare live prices across 7 listed vendors with real cost per mg, recorded COA availability and discount codes.
Buy CJC-1295 (no DAC) peptide starting at $25.00/purchase from 7 listed vendors. Compare 2mg, 5mg, 10mg and 20mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).
How much does CJC-1295 (no DAC) cost per month?
An illustrative CJC-1295 (no DAC) cost model works out to about $21.22 per month: Ascension Peptides's listed 10 mg purchase quantity at $35.00 with code WPA, divided into 0.2 mg amounts daily. This quantity provides 50.0 nominal portions — about 7.1 weeks at the selected cadence, before preparation losses or stability limits — for roughly $4.90 per week or $21.22 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 597 calculator runs; overall cadence comes from 137 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.
Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.
About CJC-1295 (no DAC)
Pre-clinical / research-onlyAlso known as: Mod GRF 1-29 · Modified GRF(1-29) · CJC-1295 No DACCJC-1295 without DAC (also called Mod GRF 1-29) is a GHRH-analog research peptide most often sourced for GH-axis protocols, usually stacked with ipamorelin. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
What to check before you buy CJC-1295 (no DAC):
- A third-party COA with mass-spec confirmation that you are getting the no-DAC variant (Mod GRF 1-29) — important because it is easily confused with the long-acting CJC-1295 DAC, a different molecule.
- A COA dated within the last 6–12 months that matches the exact vial size and batch you are buying.
- Accurate vial fill: a 5mg label should assay close to 5mg. Under-filled or mislabeled vials are a common failure mode, and they throw off every reconstitution calculation.
A Phase 1 pharmacokinetic study of CJC-1295 in healthy adults (Teichman et al., JCEM 2006) reported dose-dependent and sustained elevation of IGF-1 with the DAC-conjugated version; the no-DAC variant has not been the subject of a published Phase 1 trial of its own.[2] Research interest persists in combination protocols with selective ghrelin-receptor agonists (e.g. ipamorelin) to drive synergistic, physiologic GH pulses without abolishing endogenous pulsatility.
Regulatory: Not FDA-approved. Placed on the FDA 503A "do not compound" interest list in September 2023, citing the absence of evaluable human safety data. Research-grade material only.
CJC-1295 (no DAC): Mechanisms, Half-Life & Research Data
A skimmable deep dive into how CJC-1295 (no DAC) works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
CJC-1295 without DAC – also called Mod GRF 1-29 – is a 29-amino-acid analog of growth-hormone-releasing hormone (GHRH(1-29)). The body's native GHRH(1-29) (sold pharmaceutically as sermorelin) has a serum half-life of roughly 10 minutes because the enzyme dipeptidyl peptidase-4 (DPP-4) cleaves it almost immediately after release.[5] ConjuChem introduced four amino-acid substitutions at positions 2, 8, 15, and 27 (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) to block the enzymatic cleavage sites that limit native GHRH stability, extending the no-DAC variant's half-life – commonly cited in the research community as roughly 30 minutes, though no dedicated no-DAC human PK trial has been published.[1][4] Unlike its long-acting sister molecule CJC-1295 DAC, the no-DAC variant lacks the maleimide-propionic-acid linker that covalently binds it to circulating serum albumin – so it produces a brief, near-physiologic burst of GHRH-receptor stimulation on pituitary somatotropes that triggers a single GH pulse rather than the multi-day continuous receptor exposure of the DAC variant.[4] In practice it functions as a sermorelin-like molecule with a modestly longer half-life: a few-fold longer than sermorelin, but orders of magnitude shorter than CJC-1295 DAC. Community protocols commonly run 100–200 µg subcutaneous two or three times daily, almost always paired with a selective ghrelin-receptor (GHS-R1a) agonist such as ipamorelin to recruit a complementary GH-release pathway; these are protocol conventions rather than doses established by a published no-DAC dose-response trial.[6][7]
Active research areas
- Combination with ipamorelin to mimic physiologic GH pulsingThe most-studied protocol pairs CJC-1295 no-DAC with the selective ghrelin-receptor agonist ipamorelin. The two molecules engage complementary GH-release pathways (GHRH receptor and GHS-R1a), which appears in animal and small human work to produce a larger, more pulsatile GH signal than either component alone – preserving the body's natural pulse architecture rather than flattening it.[4][6][7]
- Adult growth hormone deficiency (cross-class evidence)Direct Phase 2/3 trials of no-DAC CJC-1295 in adult growth hormone deficiency have not been published. The applicable evidence base is cross-class data on GHRH analogs – primarily sermorelin (FDA-approved historically for paediatric short stature, now discontinued for commercial reasons) and tesamorelin (FDA-approved for HIV-associated lipodystrophy).[5][7]
- Sleep architecture and slow-wave sleepGHRH activity is mechanistically linked to slow-wave-sleep generation in healthy humans, generating interest in pre-bed GHRH-analog dosing as a sleep-depth aid.[5][7] No published randomised trial of no-DAC CJC-1295 specifically in sleep architecture is available; the supporting evidence is extrapolated from native GHRH and sermorelin work.
- Body composition in age-related GH declineSigalos and Pastuszak reviewed the growth-hormone-secretagogue class (including GHRH analogs and ghrelin-receptor agonists) and concluded that the published safety data are reasonable but that high-quality efficacy data in age-related GH decline remain sparse.[7] No trial-quality data exist on no-DAC CJC-1295 in this specific indication.
Open questions & leading hypotheses (3)
- Hypothesis: CJC-1295 no-DAC is meaningfully different from sermorelin in clinical practice – not just a marketing rebrand of the same GHRH(1-29) scaffold.Evidence: The four DPP-4-blocking substitutions extend half-life from roughly 10 minutes (sermorelin) to roughly 30 minutes (no-DAC), and the longer signalling window plausibly produces a larger or longer GH pulse per dose.[1][4][5] Counter-evidence: no published head-to-head trial compares no-DAC CJC-1295 against sermorelin in the same subjects on either GH peak amplitude or IGF-1 response, so the practical clinical difference between the two molecules is extrapolated from pharmacokinetic data alone rather than from a direct efficacy comparison.
- Hypothesis: Pairing no-DAC CJC-1295 with ipamorelin produces a synergistic GH pulse larger than the sum of the two molecules dosed alone.Evidence: The GHRH-receptor and GHS-R1a pathways converge on somatotropes via distinct intracellular signalling cascades; pre-clinical and small human work suggest the combination produces a larger GH peak than either component alone.[6][7] Counter-evidence: the most direct synergy data come from the CJC-1295 with-DAC + ipamorelin literature rather than the no-DAC variant, and the magnitude of additional benefit in healthy adults at typical research doses has not been quantified in a published randomised trial.
- Hypothesis: Repeated no-DAC dosing 2–3 times daily preserves the body's natural pulsatile GH pattern in a way that DAC-conjugated long-acting GHRH analogs cannot.Evidence: The pharmacokinetic profile of the no-DAC variant is much shorter, producing a near-physiologic GH pulse on each dose and falling back to baseline between doses – which preserves the negative-feedback architecture of the GH axis on paper.[4][7] Counter-evidence: even Ionescu and Frohman's analysis showed that pulsatility is partially preserved under continuous GHRH stimulation,[4] so the "DAC flattens pulses, no-DAC preserves them" framing may overstate a real but graded difference; direct long-term comparisons in humans are absent.
What community users report
Anecdotal — not controlled-trial evidence
On r/Peptides and r/PeptideAdmin, the dominant no-DAC CJC-1295 protocol pairs the peptide with ipamorelin at 100–200 µg each, dosed 2–3 times per day (most commonly pre-bed, fasted morning, and post-workout), with users explicitly choosing the no-DAC variant over the DAC variant when they want to "preserve natural GH pulsing" rather than continuously elevate IGF-1.[8][9] Reported effects skew toward subjective sleep depth, faster recovery, and modest body-composition shifts over 8–12 weeks; reported side effects are usually limited to injection-site reactions, transient flushing, and occasional head-rush right after dosing. **These reports are anecdotal and have not been validated in controlled trials.** They illustrate how users are running the peptide, but do not establish that no-DAC CJC-1295 is safe or effective for any indication, including body composition, sleep, or age-related GH decline.
Sources & references (9)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Jetté L et al. hGRF1-29-albumin bioconjugates activate the GHRH receptor and release GH and IGF-I in healthy male volunteers. Endocrinology 2005;146:3052–3058. · PMID: 15817669 link
- [2]Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. JCEM 2006;91:799–805. · PMID: 16352683 link
- [3]FDA 503A Bulks List — CJC-1295 entry, September 2023. link
- [4]Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. JCEM 2006. link
- [5]Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006;1:307–308. · PMID: 18046908 link
- [6]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552–561. · PMID: 9849822 link
- [7]Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev 2018;6:45–53. link
- [8]Community report – r/Peptides CJC-1295 no-DAC + ipamorelin protocol threads (subreddit), accessed May 2026. link
- [9]Community report – r/PeptideAdmin GHRH/GHRP stack discussions (subreddit), accessed May 2026. link
What CJC-1295 (no DAC) Costs Right Now
WPA currently tracks CJC-1295 (no DAC) from 7 distinct vendors across 9 separate CJC-1295 (no DAC) listings. In-stock CJC-1295 (no DAC) vials run from $25 to $386.55 — a 15.5x spread for the same compound. Ascension Peptides holds the lowest sticker price at $25. Normalized to milligrams, CJC-1295 (no DAC) costs $3.50/mg to $19.33/mg on this page. The best per-milligram value is the listed 10 mg purchase quantity from Ascension Peptides.
CJC-1295 (no DAC) is stocked in 4 sizes: 10 mg listed quantity; vial count not recorded; 5 mg listed quantity; vial count not recorded; 20 mg listed quantity; vial count not recorded; 2 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.
Ranked by true cost per milligram, the CJC-1295 (no DAC) listings WPA tracks are: Ascension Peptides — 10mg at $35 ($3.50/mg), COA purity 99.23%; Ascension Peptides — 5mg at $25 ($5.00/mg), COA purity 99.62%; Southern Aminos — 10mg at $50.15 ($5.01/mg), COA purity 99.75%; Paramount Peptides — 10mg at $62.18 ($6.22/mg), COA purity 99.60%; Peptira — 10mg at $67.15 ($6.72/mg), COA purity 99.88%.
CJC-1295 (no DAC) COA Coverage Across Tracked Vendors
9 of the 9 tracked CJC-1295 (no DAC) listings (100%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 9 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.09% to 99.88%. 6 listings record more CJC-1295 (no DAC) in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 7/26.
To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the CJC-1295 (no DAC) offer. WPA's listing fields do not establish that a report was independently verified.
CJC-1295 (no DAC) Calculator Input Observations
In lifetime CJC-1295 (no DAC) calculator inputs, 200mcg is the most frequent entered amount (117 of 597 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (35 of 137 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 200mcg, 5x/week is most frequent (8 of 24 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 20 mg of listed product divided by 0.2 mg gives roughly 100 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.
CJC-1295 (no DAC) Discount Codes
9 of the 9 tracked CJC-1295 (no DAC) listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.
About CJC-1295 (no DAC)
CJC-1295 without DAC (also called Mod GRF 1-29) is a GHRH-analog research peptide most often sourced for GH-axis protocols, usually stacked with ipamorelin. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
CJC-1295 (no DAC) is tracked under the Muscle Peptides category on WPA. Its reported half-life is ~30 min. Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved.
How to Read the CJC-1295 (no DAC) Comparison
- Price per milligram — Every CJC-1295 (no DAC) listing is normalized to $3.50/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
- COA metadata and purity — 9 CJC-1295 (no DAC) listings are marked for COA availability, and 9 have a recorded purity value. These fields do not independently verify a report.
- Vials sizes — The CJC-1295 (no DAC) comparison includes 2mg, 5mg, 10mg, and 20mg listed purchase quantities. Check package composition separately.
- Stock status — Live in-stock state for each CJC-1295 (no DAC) listing, refreshed on a recurring basis.
Frequently Asked Questions: CJC-1295 (no DAC)
Is it legal and safe to buy CJC-1295 (no DAC) for research?
In the US, CJC-1295 (no DAC) is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. CJC-1295 without DAC (also called Mod GRF 1-29) is a GHRH analog with no approved human form, sold for laboratory use only. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 9 CJC-1295 (no DAC) listings from 7 vendors.
How do I verify a CJC-1295 (no DAC) COA so I'm not getting an underdosed vial?
A Certificate of Analysis (COA) may report tests for a specific CJC-1295 (no DAC) batch. Check that the report identifies the compound (the short-acting no-DAC version, not the long-acting DAC variant or a CJC/ipamorelin blend), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For CJC-1295 (no DAC) specifically, 9 of 9 tracked listings (100%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 9 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 7/26.
Which CJC-1295 (no DAC) vendor should I pick?
There's no single "best" CJC-1295 (no DAC) vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. The no-DAC and DAC versions are easy to mix up, so confirm the COA names the no-DAC form specifically. 7 vendors currently carry CJC-1295 (no DAC), and Ascension Peptides holds the best true value at $3.50/mg on the 10 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.
How much does CJC-1295 (no DAC) cost — and how do I know I'm not overpaying?
Judge CJC-1295 (no DAC) by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It commonly ships in 5 mg and 10 mg vials, and the 10 mg vial usually wins on $/mg. Tracked CJC-1295 (no DAC) listings currently run $3.50/mg to $19.33/mg across 2mg, 5mg, 10mg, 20mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.
How much CJC-1295 (no DAC) do I need for one full cycle?
In lifetime CJC-1295 (no DAC) calculator inputs, 200mcg is the most frequent entered amount (117 of 597 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (35 of 137 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 200mcg, 5x/week is most frequent (8 of 24 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 20 mg purchase quantity by 0.2 mg gives roughly 100 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.
Are discount codes available for CJC-1295 (no DAC)?
Participating CJC-1295 (no DAC) vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 9 of the 9 tracked CJC-1295 (no DAC) listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.
What's the difference between CJC-1295 with DAC and without DAC?
CJC-1295 without DAC (also called Mod GRF 1-29) has a short half-life and is dosed more frequently, while the DAC version has a much longer half-life and a different dosing schedule. They are functionally distinct compounds, so WPA lists them separately — confirm the COA names the no-DAC form before comparing prices, since they aren't interchangeable.
Where can I compare CJC-1295 (no DAC) prices and listing details?
This comparison shows 9 tracked listings for CJC-1295 (no DAC) in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.